Monte carlo simulation study on dose enhancement by gold nanoparticles in brachytherapy

Radiation dose enhancement by injection of a high atomic number (Z) material into tumor volumes has been studied for various radiation sources and different concentrations of gold nanoparticles. Brachytherapy employs low energy photons of less than ∼0.5 MeV, which indeed is the optimal energy range for radiation dose enhancement by introduction of high-Z material. The present study uses the MCNPX™ code to estimate the dose enhancement by gold nanoparticles for the four common brachytherapy sources (¹³⁷Cs, ¹⁹²Ir, ¹²⁵I, and ¹⁰³Pd). Additionally, cisplatin (H₆Cl₂N₂Pt), a platinum-based chemotherapeutic drug, was used to evaluate the dose enhancement. The simulated source models were evaluated with reference to the calculated TG-43 parameter values. The dose enhancement in the tumor region due to the gold nanoparticles and cisplatin was evaluated according to the dose enhancement factor (DEF). The maximum values of the average DEFs were found to be 1.03, 1.11, 3.43, and 2.17 for the ¹³⁷Cs, ¹⁹²Ir, ¹²⁵I, and ¹⁰³Pd sources, respectively. The dose enhancement values for the low-energy sources were significantly higher than those for the high-energy sources. The dose enhancement due to cisplatin was calculated by using the same approach and was found to be comparable to that of the gold nanoparticles. The maximum value of the average DEF for cisplatin was 1.12 for the 5% concentration level in water and a ¹⁹²Ir source. We confirmed that cisplatin could be applied to cancer therapy that combines chemotherapeutic drugs with radiation therapy. The results presented herein will be used to study dose enhancement in tumor regions using various radiation modalities with high atomic number materials.